Hurwitz, H., Mitchell, E. P., Cartwright, T., Kwok, A., Hu, S., McKenna, E., & Patt, Y. Z. (2012). A Randomized, Phase II Trial of Standard Triweekly Compared with Dose-Dense Biweekly Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer: XELOX-A-DVS (Dense Versus Standard). AlphaMed Press.

Hurwitz, Herbert, Edith P. Mitchell, Thomas Cartwright, Ambrose Kwok, Sylvia Hu, Edward McKenna, and Yehuda Z. Patt. A Randomized, Phase II Trial of Standard Triweekly Compared With Dose-Dense Biweekly Capecitabine Plus Oxaliplatin Plus Bevacizumab As First-Line Treatment for Metastatic Colorectal Cancer: XELOX-A-DVS (Dense Versus Standard). AlphaMed Press, 2012.

Hurwitz, Herbert, et al. A Randomized, Phase II Trial of Standard Triweekly Compared With Dose-Dense Biweekly Capecitabine Plus Oxaliplatin Plus Bevacizumab As First-Line Treatment for Metastatic Colorectal Cancer: XELOX-A-DVS (Dense Versus Standard). AlphaMed Press, 2012.